Volume 23, Number 9—September 2017
Dispatch
Epidemiology of Neisseria gonorrhoeae Gyrase A Genotype, Los Angeles, California, USA
Ashima A. Bhatti, Lao-Tzu Allan-Blitz, Mariana Castrejon, Romney Humphries, Peera Hemarajata, and Jeffrey D. Klausner
Table
Characteristics of 110 patients infected with Neisseria gonorrhoeae containing gyrase A mutant and wild-type genes, UCLA Health, Los Angles, California, USA, November 1, 2015–August 31, 2016*
| Characteristic |
No. (%) |
No. (%) with gyrA mutant gene |
Prevalence ratio (95% CI) |
p value† |
| No. patients |
110 |
48 (44) |
||
| Age, y, n = 110 | ||||
| 17–34 | 68 (62) | 29 (43) | 1 | Referent |
| >35 |
42 (38) |
19 (45) |
1.1 (0.69–1.6) |
0.79 |
| Sex and sexual orientation, n = 110 | ||||
| Men who have sex with men | 58 (53) | 25 (43) | 1 | Ref |
| Men who have sex with women only | 11 (10) | 6 (55) | 1.3 (0.68–2.3) | 0.48 |
| Men of unknown orientation | 21 (19) | 10 (48) | 1.1 (0.65–1.9) | 0.72 |
| Women |
20 (18) |
7 (35) |
0.81 (0.42–1.6) |
0.52 |
| Race/ethnicity, n = 110 | ||||
| White | 42 (38) | 16 (38) | 1 | Referent |
| Hispanic | 12 (11) | 3 (25) | 0.66 (0.23–1.9) | 0.51‡ |
| Black/African American | 20 (18) | 12 (60) | 1.6 (0.93– 2.7) | 0.11 |
| Asian or Indian | 5 (5) | 2 (40) | 1.1 (0.37–6.8) | 1‡ |
| Other or nonspecified |
31 (28) |
15 (48) |
1.3 (0.75–2.2) |
0.38 |
| HIV infection status, n = 95 | ||||
| Uninfected | 55 (58) | 24 (44) | 1 | Referent |
| Infected |
40 (42) |
18 (45) |
1.03 (0.65–1.6) |
0.89 |
| Genotype by anatomic site, n = 125 samples | ||||
| Pharyngeal | 19 (15) | 5 (26) | 1 | Referent |
| Cervical/vaginal | 7 (5.6) | 3 (43) | 1.6 (0.52–5.1) | 0.64‡ |
| Rectal | 35 (28) | 17 (49) | 1.8 (0.81–4.2) | 0.11 |
| Urethral |
64 (51) |
27 (42) |
1.6 (0.72–3.6) |
0.21 |
| History of N. gonorrhoeae infection, n = 77 | ||||
| No | 55 (71) | 21 (38) | 1 | Referent |
| Yes |
22 (29) |
12 (55) |
1.4 (0.86–2.4) |
0.19 |
| Other sexually transmitted infections, n = 110 | ||||
| None | 71 (65) | 33 (46) | 1 | Referent |
| Chlamydia trachomatis | 31 (28) | 13 (42) | 0.90 (0.56–1.5) | 0.67 |
| Treponema pallidum | 6 (5) | 1 (17) | 0.36 (0.06–2.2) | 0.22‡ |
| Trichomonas vaginalis |
2 (2) |
1 (50) |
1.1 (0.26–4.4) |
1‡ |
| Pregnant, n = 16 | ||||
| No | 10 (63) | 3 (30) | 1 | Referent |
| Yes |
6 (37) |
2 (33) |
1.1 (0.25–4.9) |
1‡ |
| Recent methamphetamine or heroin use, n = 66 | ||||
| No | 59 (89) | 30 (51) | 1 | Referent |
| Yes |
7 (11) |
3 (43) |
0.84 (0.35–2.1) |
1‡ |
| PrEP use, n = 73 | ||||
| No | 56 (77) | 22 (39) | 1 | Referent |
| Yes |
17 (23) |
8 (47) |
1.2 (0.66–2.2) |
0.57 |
| History of fluoroquinolone exposure, n = 76 | ||||
| No | 61 (80) | 26 (43) | 1 | Referent |
| Yes | 15 (20) | 9 (60) | 1.4 (0.85–2.3) | 0.23 |
| Past 3 mo | 2 (3) | 2 (100) | 2.3 (1.8–3.1) | 0.19‡ |
| Past 4–12 mo | 9 (12) | 6 (67) | 1.6 (0.91–2.7) | 0.28‡ |
| Past 13–24 mo | 4 (5) | 1 (25) | 0.59 (0.10–3.3) | 0.64‡ |
*n values indicate number of patients for which data were available or total number of samples collected. gyrA, gyrase A; PrEP, preexposure prophylaxis.
†By χ2 test unless otherwise noted.
‡By 2-sided Fisher exact test.
Page created: August 17, 2017
Page updated: August 17, 2017
Page reviewed: August 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.